Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + etoposide + dexamethasone + pegaspargase (Xinhua Hospital)
- Development stage
- Phase 2
- Lead developer
- Xinhua Hospital
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Parenteral
01
Overview
MEDA is a combination chemotherapy regimen consisting of methotrexate, etoposide, dexamethasone, and pegaspargase. It is primarily investigated for the treatment of advanced-stage (Stage IV) extranodal natural killer/T-cell lymphoma (ENKTL), nasal type. The regimen combines an antimetabolite (methotrexate), a topoisomerase II inhibitor (etoposide), a corticosteroid (dexamethasone), and an enzyme that depletes asparagine (pegaspargase). This combination is often followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) to consolidate remission in patients with this aggressive subtype of non-Hodgkin lymphoma.
- Other names
- MEDA regimenMEDA chemotherapy
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on methotrexate + etoposide + dexamethasone + pegaspargase (Xinhua Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + etoposide + dexamethasone + pegaspargase (Xinhua Hospital).